Showing results (1-10 of 8) with videos related to
Sort By:
Pageof 1
Cancer Biology & Therapy|October 7, 2004
Molecular profiling of embryonal carcinoma cells following retinoic acid or histone deacetylase inhibitor treatmentNiquiche Sangster-Guity, Li-Ming Yu, Paulette McCormickBMC Genomics|October 31, 2008
Histone deacetylase inhibitors: a new mode for inhibition of cholesterol metabolismSridar V Chittur, Niquiche Sangster-Guity, Paulette J McCormickThe Prostate|June 9, 2016
Mutational Analysis of Prostate-Specific Antigen Defines the Intrinsic Proteolytic Activity of the proPSA ZymogenNiquiche Sangster-Guity, Becky Tu-Sekine, Daniel M Raben, et al.Journal of Immunology (Baltimore, Md. : 1950)|October 12, 2010
Differential requirement of histone acetylase and deacetylase activities for IRF5-mediated proinflammatory cytokine expressionDi Feng, Niquiche Sangster-Guity, Rivka Stone, et al.Molecular Reproduction and Development|April 11, 2006
Global gene expression profiles associated with retinoic acid-induced differentiation of embryonal carcinoma cellsCheryl Eifert, Niquiche Sangster-Guity, Li-Ming Yu, et al.The Journal of Biological Chemistry|April 5, 2005
Two discrete promoters regulate the alternatively spliced human interferon regulatory factor-5 isoforms. Multiple isoforms with distinct cell type-specific expression, localization, regulation, and functionMargo E Mancl, Guodong Hu, Niquiche Sangster-Guity, et al.Arthritis and Rheumatism|January 30, 2010
Genetic variants and disease-associated factors contribute to enhanced interferon regulatory factor 5 expression in blood cells of patients with systemic lupus erythematosusDi Feng, Rivka C Stone, Maija-Leena Eloranta, et al.Human Molecular Genetics|December 8, 2007
Comprehensive evaluation of the genetic variants of interferon regulatory factor 5 (IRF5) reveals a novel 5 bp length polymorphism as strong risk factor for systemic lupus erythematosusSnaevar Sigurdsson, Harald H H Göring, Gudlaug Kristjansdottir, et al.Pageof 1